Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LGALS8 | O00214 | 2/20 | 0.45 |
| ▸ | STAT3 | P40763 | 7/20 | 0.44 |
| ▸ | IGF2R | P11717 | 1/20 | 0.43 |
| ▸ | CD209 | Q9NNX6 | 2/20 | 0.42 |
| ▸ | FGF1 | P05230 | 2/20 | 0.42 |
| ▸ | SELE | P16581 | 1/20 | 0.41 |
| ▸ | FGF2 | P09038 | 1/20 | 0.41 |
| ▸ | VEGFA | P15692 | 1/20 | 0.41 |
| ▸ | HPSE | Q9Y251 | 1/20 | 0.41 |
| ▸ | AMY1A | P0DUB6 | 1/20 | 0.40 |
| ▸ | LGALS9 | O00182 | 1/20 | 0.40 |
| ▸ | LGALS1 | P09382 | 1/20 | 0.40 |
| ▸ | LGALS3 | P17931 | 1/20 | 0.40 |
| ▸ | LGALS7; LGALS7B | P47929 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10014356 | 0.91 | LGALS8 (0.52) | LGALS8IGF2RCD209FGF1FGF2 | |
| SCHEMBL17087678 | 0.86 | LGALS8 (0.55) | LGALS8STAT3IGF2RCD209FGF1 | |
| SCHEMBL10014359 | 0.86 | IGF2R (0.50) | LGALS8STAT3IGF2RCD209FGF1 | |
| SCHEMBL19980833 | 0.85 | SELE (0.48) | LGALS8STAT3IGF2RSELEAMY1A | |
| SCHEMBL16587625 | 0.85 | SELE (0.48) | STAT3IGF2RCD209FGF1SELE | |
| SCHEMBL22026382 | 0.85 | IGF2R (0.48) | LGALS8STAT3IGF2RFGF1SELE | |
| SCHEMBL12606382 | 0.85 | AMY1A (0.43) | LGALS8STAT3FGF1AMY1ALGALS9 | |
| SCHEMBL24250550 | 0.85 | STAT3 (0.45) | LGALS8STAT3CD209FGF1SELE | |
| SCHEMBL24317962 | 0.85 | STAT3 (0.45) | LGALS8STAT3CD209FGF1SELE | |
| SCHEMBL13560177 | 0.84 | LGALS3 (0.47) | LGALS8IGF2RFGF1FGF2VEGFA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9289443-B2 | Pharmaceutical composition and method for preventing or treating hepatitis C | INDUSTRIAL TECHNOLOGY RESEARCH INSTITUTE (TW) | 2016-03-22 | — | — | US | disclosed |
| US-9289443-B2 | Pharmaceutical composition and method for preventing or treating hepatitis C | INDUSTRIAL TECHNOLOGY RESEARCH INSTITUTE (TW) | 2016-03-22 | — | — | US | disclosed |
| US-20120165279-A1 | PHARMACEUTICAL COMPOSITION AND METHOD FOR PREVENTING OR TREATING HEPATITIS C | INDUSTRIAL TECHNOLOGY RESEARCH INSTITUTE (TW) | 2012-06-28 | — | — | US | disclosed |
| US-20120165279-A1 | PHARMACEUTICAL COMPOSITION AND METHOD FOR PREVENTING OR TREATING HEPATITIS C | INDUSTRIAL TECHNOLOGY RESEARCH INSTITUTE (TW) | 2012-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120165279-A1 | PHARMACEUTICAL COMPOSITION AND METHOD FOR PREVENTING OR TREATING HEPATITIS C | LIPC, HAVCR2, LIPA | LGALS8 1603/4885STAT3 3379/4885IGF2R 4481/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.